TITLE

The Efficacy and Tolerability of AST-120 (Spherical Carbon Adsorbent) in Active Pouchitis

AUTHOR(S)
Shen, Bo; Pardi, Darrell S.; Bennett, Ana E.; Queener, Elaine; Kammer, Patricia; Hammel, Jefferey P.; LaPlaca, Caroline; Harris, M. Scott
PUB. DATE
June 2009
SOURCE
American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1468
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES:Although a majority of patients with pouchitis respond favorably to antibiotic therapy, many relapse frequently, and nonabsorbable and non-antibiotic-based agents are desirable for reducing bacterial resistance and the systemic adverse effects associated with long-term antibiotic exposure. AST-120 (a spherical carbon adsorbent) comprises highly adsorptive, porous carbon microspheres with the ability to adsorb small-molecular-weight toxins, inflammatory mediators, and harmful bile acids. The aim of this pilot trial was to evaluate the efficacy and tolerability of AST-120 in the treatment of active pouchitis.METHODS:Eligible patients were recruited from two subspecialty pouchitis clinics. Inclusion criteria were (i) ileal pouch-anal anastomosis performed for ulcerative colitis; (ii) active pouchitis with Pouchitis Disease Activity Index (PDAI) scores ≥7; and (iii) discontinuation of antibiotic therapy for at least 2 weeks. Exclusion criteria included Crohn's disease of the pouch, isolated cuffitis, pouch strictures, abscess, and sinuses. All eligible patients received AST-120 in 2-g sachets (oral) open label, thrice a day for 4 weeks. The primary efficacy end point was remission as defined by a PDAI score of <7 points; the main secondary end point was clinical response, defined by a reduction of the PDAI score of ≥3 points.RESULTS:Nineteen of 20 patients completed the trial. Eleven patients (55.0%) had a clinical response to the therapy and 10 patients (50.0%) entered remission. Median reduction in the PDAI symptom, endoscopy, and histology subscores, and PDAI total scores after 4 weeks were –2 (P=0.002), –2 (P=0.003), 0 (P=0.32), and –4 (P=0.001) points, respectively. The agent was well tolerated; one patient experienced transient mild elevation of alkaline phosphatase of uncertain significance and one patient experienced an upper respiratory infection after taking one dose of AST-120 and was excluded from the final analysis for the calculation of pre- and post-trial PDAI scores.CONCLUSIONS:AST-120 seems to be effective and well tolerated in treating patients with active pouchitis. A randomized, placebo-controlled trial is warranted for assessing the long-term efficacy and safety of AST-120 in the disease.Am J Gastroenterol 2009; 104:1468–1474; doi:10.1038/ajg.2009.138; published online 12 May 2009
ACCESSION #
40737256

 

Related Articles

  • Crohn's Disease.  // Current Medical Literature: Gastroenterology;2007, Vol. 26 Issue 3, p78 

    The article presents studies related to Crohn's disease. These include "Endoscopic balloon dilatation of intestinal strictures in Crohn's disease: Safe alternative to surgery," by Y. Ajlouni et al, "Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease:...

  • Chronic Refractory Pouchitis.  // Current Medical Literature: Gastroenterology;2007, Vol. 26 Issue 4, p111 

    The article discusses a couple of researches being done on chronic refractory pouchitis (CRP). The first study evaluates the small intestine in CRP using wireless capsule endoscopy. In the other study, the authors examined the use of oral budesonide, an effective treatment for inflammation of...

  • Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Voclerhoizer, W. A.; Beinhoelzl, J.; Rogalla, P.; Murrer, S.; Schachschol, G.; Lochs, H.; Ortner, M-A. // Gut;Mar2005, Vol. 54 Issue 3, p369 

    Background: Wireless capsule endoscopy (WCE) offers endoscopic access to the small bowel and may therefore change diagnostic and therapeutic strategies in small bowel diseases. Aim: The aim of this prospective study was to validate the gain in information and therapeutic impact of WCE in...

  • The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Henderson, Paul; Anderson, Niall H; Wilson, David C // American Journal of Gastroenterology;May2014, Vol. 109 Issue 5, p637 

    OBJECTIVES:Fecal calprotectin (FC) is increasingly used during the diagnosis of inflammatory bowel disease (IBD), outperforming blood markers during investigation in children. Tests that reduce endoscopy rates in children with suspected gut inflammation would be beneficial. We aimed to determine...

  • Continuing Medical Education Questions: June 2010. DeVault, Kenneth R.; Atreja, Ashish; Ying Hong Wang; Kim, Karen C.; Dian Chiang // American Journal of Gastroenterology;Jun2010, Vol. 105 Issue 6, p1249 

    The article presents several questions and answers related to capsule endoscopy (CE) including yield of CE in patients with suspected and established Crohn's disease (CD), the diagnostic yield of CE in patients with suspected CD and findings of the CE.

  • EDITOR'S QUIZ: GI SNAPSHOT.  // Gut;Aug2007, Vol. 56 Issue 8, p1164 

    The article discusses the use of wireless capsule endoscopy (WCE) in the diagnosis of multiple aphtoid ulcerations of the small intestine in a woman with Crohn's disease (CD). It is accounted that the use of WCE is usually enough evidence to direct the appropriate treatment for CD. Since the...

  • Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis/Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes Balzola, Federico; Cullen, Garret; Hoentjen, Frank; Ho, Gwo-Tzer; Russell, Richard // Inflammatory Bowel Disease Monitor;2013, Vol. 13 Issue 4, p159 

    The article discusses the role of fecal calprotectin (FC) assessment in diagnosis of patients with inflammatory bowel diseases (IBD). It states that FC was the best predictor of endoscopic activity and the only parameter that could reliably discriminate between different levels of endoscopic...

  • Crohn's disease in a Meckel's diverticulum: report of a case. Diamond, Ivan R.; Hayes-Jordan, Andrea; Phillips, M. James; Langer, Jacob C. // Pediatric Surgery International;Mar2008, Vol. 24 Issue 3, p361 

    Meckel's diverticulum has previously been reported to be present in patients with Crohn's disease. However, the finding is typically an incidental one, and involvement of the diverticulum in the disease process is uncommon. We report a case of an adolescent with known Crohn's disease who...

  • The prevalence and outcome of jejunal lesions visualized by small bowel endoscopy in Crohn's disease. Balzola, Federico; Cullen, Garret; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2013, Vol. 14 Issue 1, p26 

    The article presents a study that determines the prevalence and outcome of jejunal lesions in patients with Crohn's disease. It describes the method of the study that uses small bowel capsule endoscopy for accurate visualization of lesions on the mucosal surface. It notes the result of the study...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics